High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis
- 1 October 2016
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 151 (4), 651-659.e1
- https://doi.org/10.1053/j.gastro.2016.07.020
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesAnnals of Internal Medicine, 2015
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- Hepatitis CThe Lancet, 2015
- New Hepatitis C Therapies: The Toolbox, Strategies, and ChallengesGastroenterology, 2014
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- The impact of hepatitis C burden: an evidence‐based approachAlimentary Pharmacology & Therapeutics, 2014
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CHepatology, 2011
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trialHepatology, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006